Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Ridder

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
BJU International|December 18, 2003
Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding studyC R Chapple, P Araño, J L H R Bosch, et al.
The Journal of Investigative Dermatology|October 1, 1994
Increases in human epidermal DR+CD1+, DR+CD1-CD36+, and DR-CD3+ cells in allergic versus irritant patch test responsesG F Gerberick, L A Rheins, C A Ryan, et al.
Blood Pressure Monitoring|March 27, 2018
A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trialMichael A Weber, Christopher R Chapple, Christian Gratzke, et al.
Journal of Cell Science|February 21, 1998
The combination of epidermal growth factor and transforming growth factor-beta induces novel phenotypic changes in mouse liver stem cell linesR J Isfort, D B Cody, S B Stuard, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
BJU International|December 18, 2003
Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding studyC R Chapple, P Araño, J L H R Bosch, et al.
The Journal of Investigative Dermatology|October 1, 1994
Increases in human epidermal DR+CD1+, DR+CD1-CD36+, and DR-CD3+ cells in allergic versus irritant patch test responsesG F Gerberick, L A Rheins, C A Ryan, et al.
Blood Pressure Monitoring|March 27, 2018
A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trialMichael A Weber, Christopher R Chapple, Christian Gratzke, et al.
Journal of Cell Science|February 21, 1998
The combination of epidermal growth factor and transforming growth factor-beta induces novel phenotypic changes in mouse liver stem cell linesR J Isfort, D B Cody, S B Stuard, et al.
Pageof 5